Reuters logo
BRIEF-MolMed and Rocket Pharma sign collaboration agreement for treatment of Fanconi Anemia
February 27, 2017 / 6:16 AM / 7 months ago

BRIEF-MolMed and Rocket Pharma sign collaboration agreement for treatment of Fanconi Anemia

Feb 27 (Reuters) - MolMed SpA:

* MolMed and Rocket Pharma establish a collaboration agreement in the field of gene therapy for the treatment of Fanconi Anemia

* Rocket Pharma is a U.S. gene therapy company

* MolMed will develop and manufacture the lentiviral vectors to be used for the ex-vivo transduction of hematopoietic stem cells, as part of the manufacturing process of Rocket’s cellular therapy products Source text: www.1info.it Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below